National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Zanubrutinib (Brukinsa®). HTA ID: 21044

Zanubrutinib (Brukinsa®) is indicated as monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 11/10/2021
Rapid review completed 16/11/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that zanubrutinib (Brukinsa®) not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.